US FDA Shelves Proposal To Mandate Home-Use Device E-Labeling
Executive Summary
A controversial 2016 proposed rule that would have required manufacturers of many class II and class III home-use devices to electronically submit device labeling information to US FDA will not be finalized, the agency affirmed in the Oct. 17 HHS Unified Agenda document. The agency also signaled plans to imminently finalize a broad device classification rule, and other updates.
You may also be interested in...
After Years Of Waiting, FDA Classifies Anthrax Detection Devices As Class II
A new guidance document and final rule from US FDA on Bacillus bacteria detection devices, which are used to diagnose anthrax, place the pre-amendment devices in class II.
FDA Cancels Proposed Rule On Clinical Trial Malfeasance
US FDA has withdrawn a proposed rule that would have required sponsors to notify FDA if they became aware of data falsification during a clinical trial. Industry had been critical of the 2010 proposal.
QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like
US FDA will face high hurdles as it works to write a new rule that would merge the agency's Quality System Regulation with international quality systems standard ISO 13485. That's according to Kim Trautman, a longtime industry insider who wrote the QSR in the early to mid-1990s. "It’s a clear heavy lift from a regulatory policy perspective" that could take as long as five years to complete, she says. In the meantime, Trautman offers some insight into what device-makers might see in a new hybrid quality systems regulation from FDA. She addresses everything from corrective and preventive action (CAPA) to labeling, and complaint handling to risk management – and more.